Precision Medicine Approaches For Heterogeneous Conditions Such As Autism Spectrum Disorders The Need For A Biomarker Exploration Phase In Clinical Trials Phase 2m
Download Precision Medicine Approaches For Heterogeneous Conditions Such As Autism Spectrum Disorders The Need For A Biomarker Exploration Phase In Clinical Trials Phase 2m PDF/ePub or read online books in Mobi eBooks. Click Download or Read Online button to get Precision Medicine Approaches For Heterogeneous Conditions Such As Autism Spectrum Disorders The Need For A Biomarker Exploration Phase In Clinical Trials Phase 2m book now. This website allows unlimited access to, at the time of writing, more than 1.5 million titles, including hundreds of thousands of titles in various foreign languages.
Precision medicine approaches for heterogeneous conditions such as autism spectrum disorders (The need for a biomarker exploration phase in clinical trials - Phase 2m)
Author: David Quentin Beversdorf
language: en
Publisher: Frontiers Media SA
Release Date: 2023-04-17
Many therapeutic interventions for autism spectrum disorder fail when they are examined in a clinical trial. Frequently, there is a subset of patients that responds very well to the intervention, while others do not, and the overall result does not yield a positive result. As autism spectrum disorder is highly heterogeneous in its underlying genetics and other etiological risk factors, as well as its heterogeneous phenotypic manifestation, this variability in response to any specific treatment is not entirely surprising. However, it remains a challenge to meaningfully subtype this heterogeneity for targeted treatment. The purpose of this research topic is to solicit articles that address the heterogeneity in autism spectrum disorder in a manner that may meaningfully contribute to targeted treatment approaches. Studies that address the heterogeneity of autism that could theoretically lead to targeted treatment, and studies that more directly address the use of a marker in association with response to a treatment, are both aspects that will contribute to this purpose. It is hoped that this Research Topic will yield articles that can help advance the field towards precision medicine in autism spectrum disorders. Manuscripts that contribute to the specification of the heterogeneity of autism spectrum disorder in a manner that could theoretically lead to targeted treatment would be appropriate for this research topic. Additionally, articles that utilize subtyping in relation to response to treatment would be appropriate for this research topic.
Developmental Trajectories, Diagnosis, and Interventions for Autism
This book introduces a developmental psychopathology approach to exploring the concept of autism in terms of three broad domains of development— physical, cognitive, and psychosocial—that are inextricably linked. Developmental psychopathology focuses on the interplay between normal and abnormal development. The juxtaposition of typical and atypical developmental patterns can better inform clinicians and parents of possible signs of achievement milestones that are missing or falling behind. This book consists of twelve chapters grouped under four parts, with each chapter's core content based on the most recent research findings and ending with the author's reflections on various parts of the chapter and a summary of the main points discussed. A final chapter addresses topics of utmost importance rarely discussed in books on autism. Appropriate for a wide range of professionals who work with clients who have autism, this book is a unique resource with approaches often overlooked in most books on autism.
Neurophysiologic Biomarkers in Neuropsychiatric Disorders
This book reviews neurophysiological biomarkers in neuropsychiatric disorders from the viewpoint of the 21st Century Cures Act, which encourages the use of biomarkers for a variety of purposes during drug development. It covers both traditional etiologic uses of biomarkers and the more recent Biomarkers, EndpointS, and other Tools (BEST) classification scheme used by the FDA, which permits biomarkers for purposes of susceptibility, diagnosis, monitoring, prognosis, pharmacodynamics/response, and safety. The first section of the book describes potential uses of neurophysiologic biomarkers. Subsequent sections focus on a wide range of conditions, including schizophrenia, autism spectrum disorder, Parkinson’s disease, and depression, as well as cross-diagnostic and translational uses, including monkey and rodent analogs. The purpose of the book is to help clinicians understand how neurophysiological biomarkers may be used to understand and manage clinical conditions; to help researchers to understand how biomarkers may be used translationally to test specific theories; and to help pharma investigators to understand how biomarkers can be used to accelerate treatment development.